XML 69 R55.htm IDEA: XBRL DOCUMENT v3.23.3
Fair Value Measurements and Investments - Schedule of Valuation Methodology and Unobservable Inputs for Level 3 Assets and Liabilities Measured at Fair Value (Detail) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Spinal Kinetics [Member] | Fair Value, Inputs, Level 3 [Member]    
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]    
Contingent consideration estimated fair value   $ 17,200
Decrease in fair value recognized in acquisition-related amortization and remeasurement   $ (17,200)
Lattus Spine [Member]    
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]    
Consideration transferred $ 9,100  
Counterparty discount rate 9.50%  
Revenue risk-adjusted discount rate 7.00%  
Lattus Spine [Member] | Fair Value, Inputs, Level 3 [Member]    
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]    
Contingent consideration estimated fair value $ 11,200  
Decrease in fair value recognized in acquisition-related amortization and remeasurement (2,100)  
Contingent consideration estimated fair value at September 30 9,100  
Neo Medical [Member]    
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]    
Neo Medical Convertible Loan $ 7,670  
Fair value discount rate 19.40%  
Estimated equity volatility 80.60%